Fludarabine in lymphoproliferative malignancies: a single-centre experience.

Simple item page
dc.contributor.authorPrabhash, Ken_US
dc.contributor.authorVikram, G Sen_US
dc.contributor.authorNair, Ren_US
dc.contributor.authorSengar, Men_US
dc.contributor.authorGujral, Sen_US
dc.contributor.authorBakshi, Aen_US
dc.contributor.authorGupta, Sen_US
dc.contributor.authorParikh, P Men_US
dc.date.accessioned2008-07-10en_US
dc.date.accessioned2009-06-03T05:27:57Z
dc.date.available2008-07-10en_US
dc.date.available2009-06-03T05:27:57Z
dc.date.issued2008-07-10en_US
dc.description.abstractBACKGROUND: Fludarabine has been reported to be an effective drug for the treatment of chronic lymphocytic leukaemia (CLL) and indolent lymphomas. However, its safety and efficacy in Indian patients has not been studied. We retrospectively analysed our experience with fludarabine in low grade lymphomas and CLL. METHODS: The records of all patients with low grade lymphoma or CLL who received fludarabine between April 1999 and November 2006 were analysed. Response evaluation was done as per the National Cancer Institute-Working Group guidelines for CLL and International Workshop criteria for non-Hodgkin lymphomas, respectively, in those patients who received at least 3 cycles of fludarabine. Toxicity was graded as per the common terminology criteria for adverse events, version 3.0. Median event-free survival was obtained using Kaplan-Meier survival analysis. RESULTS: Forty-seven patients were included in the study and 189 cycles were administered (median: 4 cycles per patient). Sixteen patients had a treatment delay, 14 due to myelosuppression. Twenty-five patients had low grade lymphoma and 22 had CLL. The response was evaluable in 22 patients with low grade lymphoma and 20 with CLL. The overall response rate for CLL was 100% in those treated upfront (n=9) and 55% in those with relapsed disease (n=11). The overall response rate for low grade lymphoma was 88% (63% complete remission) in untreated patients and 79% (43% complete remission) in those with relapsed disease. Common adverse events were myelosuppression and infection. Two patients died of sepsis and 4 due to disease progression on treatment. Median event-free survival for patients treated upfront with fludarabine was 31.4 months. CONCLUSION: In our patient population, response to fludarabine is similar to that in the published literature. Our patients had a higher frequency of haematological toxicity.en_US
dc.description.affiliationDepartment of Medical Oncology, Tata Memorial Hospital, Dr Ernest Borges Marg, Parel, Mumbai 400012, Maharashtra, India.en_US
dc.identifier.citationPrabhash K, Vikram GS, Nair R, Sengar M, Gujral S, Bakshi A, Gupta S, Parikh PM. Fludarabine in lymphoproliferative malignancies: a single-centre experience. National Medical Journal of India. 2008 Jul-Aug; 21(4): 171-4en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/118386
dc.language.isoengen_US
dc.source.urihttps://www.nmji.inen_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAntineoplastic Agents --adverse effectsen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshLeukemia, Lymphoid --drug therapyen_US
dc.subject.meshLymphoma --drug therapyen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshRetrospective Studiesen_US
dc.subject.meshSurvival Analysisen_US
dc.subject.meshVidarabine --adverse effectsen_US
dc.titleFludarabine in lymphoproliferative malignancies: a single-centre experience.en_US
dc.typeJournal Articleen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
National Medical Journal of India